Shares of Centrus Energy vaulted 13.8% to $101.31 Friday after Roth/MKM analyst Joe Reagor upgraded the nuclear fuel supplier from Neutral to Buy, keeping his $115 price target. The firm's central concern had been a potential revenue cliff in 2028 tied to the U.S. ban on Russian uranium imports, which takes effect January 1, 2028.
Roth said Centrus has "mitigated this near-term risk significantly through its recent contract and acquisition." The upgrade lands just two days after a mixed earnings report that forced investors to weigh ugly near-term numbers against a far brighter long-term story.
• Revenue Is Falling, but the Headline Profit Number Is Misleading. Quarterly revenue declined 26% to $55.5 million from $74.9 million, reflecting lower uranium sales volumes and reduced revenue from government contracts.
The earnings beat — GAAP net income of $31.6 million — was primarily driven by a $46.4 million gain from the revaluation of warrant liabilities rather than stronger underlying operations.
Stripping that out, Centrus posted an adjusted net loss of $9.4 million, or −$0.46 per share, versus a $5.2 million profit a year ago. Investors buying today's rally on the GAAP headline should look under the hood.
• A Massive Backlog Tells a Different Story Than This Quarter's Sales. Centrus grew its contingent enrichment backlog to $5.4 billion , and total backlog stood at $7 billion as of September 30, with contract durations extending to 2040. That pipeline dwarfs the company's current annual revenue run rate and signals that utilities are locking in long-term domestic fuel supply — a bet that matters as Russian imports face a regulatory cutoff. The disconnect between today's revenue and tomorrow's contractual commitments is the core tension in the stock.
• Centrifuge Manufacturing Ahead of Schedule Changes the Risk Profile. Centrus completed manufacturing and began shipping centrifuges from Oak Ridge, Tennessee, ahead of its year-end target, and finalized all critical supply-chain contracts early.
Management said this "puts us far ahead of the competition." Execution risk — the chance that expansion plans slip — has been the biggest overhang on the stock. Delivering hardware early reduces that discount.
• Wall Street Remains Split. Overall analyst sentiment is "Moderate Buy," with a consensus price target of $193.12 — nearly double today's price. Yet Bank of America recently cut its target from $240 to $205 with a "Neutral" rating , and another firm dropped its target from $180 to $120. Roth's $115 target sits well below the consensus, meaning even the bull case here is conservative relative to the Street. The real question: can Centrus convert a towering backlog into actual cash before the Russian import ban reshuffles the fuel market?